<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421314</url>
  </required_header>
  <id_info>
    <org_study_id>C21-16</org_study_id>
    <nct_id>NCT03421314</nct_id>
  </id_info>
  <brief_title>Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment.</brief_title>
  <official_title>Effect of Zinc and Selenium Supplementation on Clinical and Immunological Parameters on HIV+ Individuals on Antiretroviral Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Enfermedades Respiratorias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of zinc gluconate and/or selenium yeast
      supplementation during six months on clinical (glucose, cholesterol, triglycerides, bone
      mineral density and body composition) and immunological (oxidative stress, CD4+ count and
      pro-inflammatory cytokines) parameters in a population with HIV diagnosis on antiretroviral
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected individuals on antiretroviral treatment have lowest risk of AIDS events and more
      life expectancy. However, antiretroviral treatment does not fully restore the immune system
      in all individuals due to persistent immune activation and inflammation, increasing the risk
      of non-AIDS complications, such as insulin resistance, diabetes, hypertension, dyslipidemia,
      obesity, low bone mass density, oxidative stress and micronutrient deficiencies. Several
      studies showed that HIV+ patients present zinc and selenium deficiency. Those micronutrients
      are involved in the pathogenesis of metabolic complications and have a major role in
      maintaining immune system function. It remains unknown the effect of zinc and selenium
      supplementation on metabolic and immunological parameters associated to non-AIDS
      complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 23, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in zinc and selenium plasmatic levels</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>We evaluated the effects of zinc (30mg/d) and selenium (200μg/d) supplementation on plasma zinc and selenium levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Counts of CD4+ T cells</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting serum glucose</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid peroxidation</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Measure by TBARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proinflammatory cytokine profile</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Measure by LUMINEX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone metabolism biomarkers</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Changes in osteoprotegerin and RANKL levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD4+ T cells</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>Measure by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL cholesterol</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL cholesterol</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fat mass</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lean soft tissue</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>in Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in and bone mineral density</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
    <description>g/cm3</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>HIV</condition>
  <condition>ART</condition>
  <condition>Zinc Deficiency</condition>
  <condition>Selenium Deficiency</condition>
  <condition>Metabolic Complication</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zinc + Selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will not take supplementation as a control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc gluconate and/or Selenium yeast</intervention_name>
    <description>30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast</description>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_label>Zinc + Selenium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  &gt;200 CD4+ cells/mL

          -  &gt;2 years under antiretroviral treatment

          -  &gt;2 years under virology control (HIV RNA &lt;40 copies/mL)

        Exclusion Criteria:

          -  Patients with opportunistic infection

          -  Patients taking vitamin-mineral supplements

          -  Patients with moderate or high cardiovascular risk (Framingham score higher than 10%)
             and cholesterol LDL &gt;190 mg/dL or triglycerides &gt;500 mg/dL.

          -  Patients with diabetes or hypertension diagnosis.

          -  Patients taking drugs for diabetes, hypertension, dyslipidemia or low bone mass
             density.

          -  Low adherence to supplementation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Reyes Teran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal investgator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan Osuna Padilla, MD</last_name>
    <phone>56667985</phone>
    <phone_ext>109</phone_ext>
    <email>ivan.osuna@cieni.org.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Briceño Cárdenas, PhD</last_name>
    <phone>56667985</phone>
    <phone_ext>140</phone_ext>
    <email>olivia@cieni.org.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Investigaciones en Enfermedades Infecciosas</name>
      <address>
        <city>Mexico city</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Osuna Padilla, MD</last_name>
      <phone>56667085</phone>
      <phone_ext>109</phone_ext>
      <email>ivan.osuna@cieni.org.mx</email>
    </contact>
    <investigator>
      <last_name>Gustavo Reyes-Terán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Osuna Padilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia Briceño Cárdenas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Rodriguez Moguel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana Aguilar Vargas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Enfermedades Respiratorias</investigator_affiliation>
    <investigator_full_name>Gustavo Reyes-Teran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

